

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) and 1.97(c))

Docket No.
 18467

In Re Application Of: Lloyd S. Gray, et al.



Application No.	Filing Date	Attorney or Agent Name	Customer No.	Group Art Unit	Confirmation No.
10/589,216	August 11, 2006	Unassigned	23389	Unassigned	Unassigned

Title:

**INHIBITING CAV3 ISOFORMS AND THE Δ25B SPLICE VARIANTS FOR THE
 DIAGNOSIS AND TREATMENT OF CANCER**

Address to:
Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))Docket No.
18467

In Re Application of: Lloyd S. Gray, et al.

PATENT & TRADEMARK OFFICE
JAN 16 2007

Application No.	Filing Date	Attala	Customer No.	Group Art Unit	Confirmation No.
10/589,216	August 11, 2006	Unassigned	23389	Unassigned	Unassigned

Title:

INHIBITING CAV3 ISOFORMS AND THE [REDACTED] 2SB SPLICE VARIANTS FOR THE
DIAGNOSIS AND TREATMENT OF CANCER

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.

- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

January 9, 2007


(Date)

Signature of Person Mailing Correspondence

Peter I. Bernstein

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.



Signature

Dated: January 9, 2007

Peter I. Bernstein

Registration No. 43,497

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530

516-742-4343

CC:

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.X./

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****Applicant(s):** Lloyd S. Gray, et al.**Examiner:** Unassigned**Serial No:** 10/589,216**Art Unit:** Unassigned**Filed:** August 11, 2006**Docket:** 18467**For:** INHIBITING CAV3 ISOFORMS AND
THE 8 25B SPLICE VARIENTS FOR THE
DIAGNOSIS AND TREATMENT OF CANCER
Dated: January 9, 2007

Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 23313-1450

INFORMATION DISCLOSURE STATEMENT**Sir:**


In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. United States Patent No. 6,191,156 B1, dated February 20, 2001 to Kifor et al.;
2. United States Patent No. 6,255,457 B1, dated July 3, 2001 to Schnitzer; and
3. Song K.S. et al., "Expression of Caveolin-3 in Skeletal, Cardiac, and Smooth Muscle Cells", *The Journal of Biological Chemistry*, 271(25):15160-15165 (1996).

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 9, 2007


Peter I. Bernstein

The references were cited in an International Search Report dated December 18, 2006. Applicants are submitting a copy of Reference No. 3. In accordance with 37 C.F.R. § 1.98 (a)(2)(i), Applicants are not required to submit a copy of the above-cited U.S. Patent references. The relevance of the above-identified references has been described in the International Search Report.

Inasmuch as this Information Disclosure Statement is also being submitted in accordance with the schedule set out in 37 C.F.R. § 1.704(d), a statement is attached.

Respectfully submitted,



Peter I. Bernstein
Registration No.: 43,497

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

PIB:dg

JAN 16 2007

**THE UNITED STATES PATENT AND TRADEMARK OFFICE****Applicant(s):** Lloyd S. Gray, et al.**Examiner:** Unassigned**Serial No:** 10/589,216**Art Unit:** Unassigned**Filed:** August 11, 2006**Docket:** 18467**For:** INHIBITING CAV3 ISOFORMS AND
THE 8 25B SPLICE VARIENTS FOR THE
DIAGNOSIS AND TREATMENT OF CANCER**Dated:**

January 9, 2007

Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 23313-1450

STATEMENT PURSUANT TO 37 C.F.R. § 1.704(d)


Sir:

I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 9, 2007


Peter I. Bernstein

Therefore, this Information Disclosure Statement cannot be considered a failure to engage in reasonable efforts to conclude prosecution of the application under paragraphs (c)(6), (c) (8), (c) (9), or (c) (10) of 37 C.F.R. § 1.704.

Respectfully submitted,



Peter I. Bernstein
Registration No.: 43,497

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

PIB:dg